Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 7/20 | 0.39 |
| ▸ | MAOA | P21397 | 7/20 | 0.39 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883069 | 1.00 | MEN1 (0.43) | MEN1CYP2C19KMT2ASIGMAR1SLC18A3 | |
| SCHEMBL6873760 | 1.00 | MEN1 (0.43) | MEN1CYP2C19KMT2ASIGMAR1SLC18A3 | |
| SCHEMBL2527130 | 0.78 | SLC18A3 (0.47) | MEN1CYP2C19KMT2ASIGMAR1SLC18A3 | |
| SCHEMBL15652887 | 0.74 | TACR1 (0.51) | SIGMAR1SLC18A3TSHRTACR1TRPA1 | |
| SCHEMBL19852548 | 0.72 | TACR1 (0.47) | MEN1CYP2C19KMT2ASIGMAR1SLC18A3 | |
| SCHEMBL1085761 | 0.71 | MAOB (0.43) | SIGMAR1SLC18A3TRPA1KDM1AMAOA | |
| SCHEMBL18827060 | 0.71 | TRPA1 (0.46) | MEN1KMT2ASIGMAR1SLC18A3TACR1 | |
| SCHEMBL8212527 | 0.70 | TSHR (0.52) | MEN1CYP2C19KMT2ASIGMAR1SLC18A3 | |
| SCHEMBL18422847 | 0.70 | TACR1 (0.51) | KMT2ASIGMAR1SLC18A3TACR1KDM1A | |
| SCHEMBL8073204 | 0.68 | TACR1 (0.46) | MEN1CYP2C19KMT2ASIGMAR1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | MEN1 1877/4885CYP2C19 2545/4885KMT2A 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.